(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 July 2009 (16.07.2009)

PCT

(10) International Publication Number
WO 2009/087351 A1

(51) International Patent Classification:
A61K 36/185 (2006.01) *A61K 45/06* (2006.01)
A61K 31/352 (2006.01) *A61P 25/18* (2006.01)
A61K 31/35 (2006.01) *A61P 25/22* (2006.01)
A61K 31/05 (2006.01)

(21) International Application Number:
PCT/GB2008/004217

(22) International Filing Date:
17 December 2008 (17.12.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0800390.7 4 January 2008 (04.01.2008) GB

(71) Applicants *(for all designated States except US)*: **GW PHARMA LIMITED** [GB/GB]; Porton Down Science Park, Salisbury, Wiltshire SP4 0JR (GB). **OTSUKA PHARMACEUTICAL CO., LIMITED** [JP/JP]; 2-9, Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-8535 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **KIKUCHI, Tetsuro** [JP/JP]; Otsuka Pharmaceutical Co., Ltd., 10F Kitahama TNK Building, 1-7-1 Doshomachi, Chuo-ku, Osaka 541-0045 (JP). **MAEDA, Kenji** [JP/JP]; Otsuka Pharmaceutical Co., Ltd., 10F Kitahama TNK Building, 1-7-1 Doshomachi, Chuo-ku, Osaka 541-0045 (JP). **GUY, Geoffrey** [GB/GB]; GW Pharma Limited, Porton Down Science Park, Salisbury, Wiltshire SP4 0JR (GB). **ROBSON, Philip** [GB/GB]; GW Pharma Limited, Porton Down Science Park, Salisbury, Wiltshire SP4 0JQ (GB). **STOTT, Colin** [GB/GB]; GW Pharma Limited, Porton Down Science Park, Salisbury, Wiltshire SP4 0JQ (GB).

(74) Agent: **ENTRLPNEUR LIMITED**; Office 16, Egerton House, 2 Tower Road, Birkenhead, Wirral CH41 1FN (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(54) **Title:** USE OF CANNABINOIDS IN COMBINATION WITH AN ANTI-PSYCHOTIC MEDICAMENT

(57) **Abstract:** The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.

WO 2009/087351 A1